© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
May 30, 2020
“Although more evidence is needed before changing clinical practice, these are highly promising results, suggesting that (Bavencio) could prevent patients with chemo-resistant disease from the severe toxicity of chemotherapy combinations.”
May 29, 2020
When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer